FAM50B

Across TCGA pan-cancer cohorts, FAM50B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM50B data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM50B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM50B expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where FAM50B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.306	0.686	.016	14	view →
PDAC	DFS	Quartile	All	0.512	0.280	.021	12	view →
LSCC	DFS	Median	III,IV	0.452	0.886	.015	8	view →
CCRCC	DFS	Median	All	0.836	0.616	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM50B–LUAD (DFS)

Open the LUAD breakdown →